- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in...
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC -
CytomX Therapeutics: Q2 Earnings Snapshot
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational...
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027...
Barchart Research What to Expect from CTMX Earnings CTMX Generated August 5, 2026 Current Price $3.35 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 25.62% CytomX Reports Tomorrow With Analysts...
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...